NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL
The goal of this clinical trial is to determine whether pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients with negative deep minimal residue disease (MRD) can benefit from blinatumomab treatment.
The main questions it aims to answer are:
- Whether the application of blinatumomab can improve the long-term survival of next generation sequence (NGS) MRD-positive B-ALL children after consolidation therapy?
- Whether the application of blinatumomab can benefit the NGS MRD-negative B-ALL children after consolidation therapy?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Xiaojun Xu
- Phone Number: +86-571-88873450
- Email: xuxiaojun@zju.edu.cn
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Clincial dianogsis of acute lymphoblastic leukemia (B-cell type) by morphology, immunology, cytogenetics, and molecular biology (MICM).
- Age ≥1 year and <18 years.
- Informed consent signed, with the parents or guardians agreeing to a unified treatment protocol.
Exclusion Criteria:
- Age <1 year or ≥18 years.
- Immunophenotyping suggests mature B-cell leukemia, mixed-lineage leukemia, or T-cell acute lymphoblastic leukemia.
- Secondary leukemia or second tumor, CML blast phase ALL.
- Other tumors or immunodeficiency diseases present.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: EOC NGS MRD positive Group
Based on the B-ALL treatment protocol, NGS MRD levels will be monitored at the end of consolidation treatment (EOC).
If NGS MRD is positive (≥0.0001%), one course of blinatumomab (28 days) will be added after the consolidation treatment.
|
The FDA has approved blinatumomab for post-consolidation treatment in all Ph-negative B-ALL cases, regardless of MRD status.
Considering the high cost of blinatumomab and the financial burden on families, we aim to precisely identify the population who would benefit from blinatumomab and provide appropriate treatment.
|
|
Active Comparator: EOC NGS MRD negative Group A
Based on the B-ALL treatment protocol, NGS MRD levels will be monitored at the end of consolidation treatment (EOC).
If NGS MRD is negative (< 0.0001%), the IR/HR patients will be randomized into A and B two groups.
EOC NGS MRD negative Group A will be added by one course of blinatumomab (28 days) treatment after the consolidation treatment.
|
The FDA has approved blinatumomab for post-consolidation treatment in all Ph-negative B-ALL cases, regardless of MRD status.
Considering the high cost of blinatumomab and the financial burden on families, we aim to precisely identify the population who would benefit from blinatumomab and provide appropriate treatment.
|
|
No Intervention: EOC NGS MRD negative Group B
Based on the B-ALL treatment protocol, NGS MRD levels will be monitored at the end of consolidation treatment (EOC).
If NGS MRD is negative (< 0.0001%), the IR/HR patients will be randomized into A and B two groups.
EOC NGS MRD negative Group B will continue the original chemotherapy treatment plan.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
event free survival
Time Frame: From enrollment to the 3-year after the end of treatment
|
Death during induction, abandonment before complete remission, death in continuous complete remission, relapse, and secondary Death during induction, abandonment before complete remission (CR), death in continuous complete remission (CCR), relapse, and secondary malignancies were considered as events in the calculation of EFS probability.
|
From enrollment to the 3-year after the end of treatment
|
|
Relapse free survival
Time Frame: From enrollment to the 3-year after the end of treatment
|
RFS was measured by the time from achievement of CR to last follow-up or first relapse and censored at the first event (death, secondary malignancies) except relapse.
|
From enrollment to the 3-year after the end of treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Treatment-Related Adverse Events as Assessed by CTCAE v4.0
Time Frame: From enrollment to the 3-year after the end of treatment
|
From enrollment to the 3-year after the end of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Neoplastic Processes
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Leukemia, Lymphoid
- Leukemia
- Neoplasm, Residual
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Antineoplastic Agents
- Blinatumomab
Other Study ID Numbers
Other Study ID Numbers
- 2024-IRB-0307-P-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.